Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

In collaboration with partner HHP, University of Chicago Medicine's food hall at the Center for Care and Discovery (CCD) is celebrating its grand opening this ...

Foremost experts in Movement Disorders, which include the fastest-growing brain disease, will convene to share about and guide the direction of global advancements like artificial intelligence.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

SALT LAKE CITY - LifeVantage (NASDAQ:LFVN) Corporation (NASDAQ:LFVN), a company specializing in health and wellness products, has announced the results of a recent in vitro study focused on a new ...

Recent findings reveal how LifeVantage’s two-product system activates GLP-1 production through targeted gene expression and microbiome support* SALT LAKE CITY, Sept. 10, 2024 (GLOBE ...

(RTTNews) - LifeVantage Corp. (LFVN), Tuesday announced promising results of an in vitro study, investigating the combined effects of its upcoming two-product system on activating GLP-1 production ...